ECC 2013: Late Breaking Clinical Trials: EXPERT-C Trial results
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
First ever Europe-wide study reveals that even when undergraduate medical students take a compulsory course on pain, they still only receive on average 12 hours’ training
by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.
Matthias Holdhoff, MD, PHD, Assistant Professor of Oncology. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
by Elizabeth C. Smyth, MB, BCh, MSc, and David Cunningham, MD, FRCP, FMedSci – In 2000, in order to optimise service provision for patients with cancer, 34 “Cancer… read more.
CHICAGO – Five pivotal studies were released today ahead of the plenary session of the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
by Jamie Von Roenn, MD, and Charles von Gunten, MD, PhD – The call to integrate palliative care practices and principles into comprehensive cancer care, not as something… read more.
The American Society of Clinical Oncology (ASCO) kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US… read more.
CHICAGO – The American Society of Clinical Oncology (ASCO) has completed the first phase in developing several sets of interoperability standards for cancer care data and overcoming the… read more.
CHICAGO – New advances against melanoma, ovarian cancer, and colorectal cancer care were presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)…. read more.
by Bruce Sylvester – Patients with an advanced kind of lung cancer and a dysfunctional ALK gene have achieved better outcomes with the targeted investigative therapy crizotinib rather… read more.